Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Bioscience Corp. on August 1, 2019. The filing primarily discloses the retention of Integra Consulting Group LLC for investor relations services and provides a summary of the company's active licensing agreements and recent technological advancements in its DehydraTECH absorption technology.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. Specific financial details disclosed include:
- Compensation to Integra: US$12,500 monthly fee.
- Equity Issuance (Initial): 150,000 voting common shares at a deemed price of US$0.69 per share.
- Equity Issuance (Contingent): 180,000 voting common shares to be issued after the initial six-month term, valued at the fair market price on the day prior to issuance.
Material Changes and Operational Updates
The company reported significant expansion in its licensing portfolio as of August 2019:
- New Agreements: Year-to-date 2019 announcements include 11 new licenses across various partners, including Altria Ventures Inc. (oral nicotine), Nuka (CBD/hemp beverages), and Hill Street Beverages (global beverage licenses).
- Total Portfolio: Lexaria now has 9 corporate licensees utilizing 11 licenses for beverages, edibles, and oral products.
- Strategic Partnership: Engagement of Integra Consulting Group LLC for a six-month initial term to assist with US capital markets strategy and shareholder communication.
Outlook, Management Commentary, and Risks
Management Commentary: Management attributes commercial success to scientific results demonstrating the efficacy of DehydraTECH. Recent animal studies indicated that patent-pending formulations delivered over 1,900% more CBD into brain tissue and achieved peak blood levels over 800% greater than controls, with detection in the bloodstream as early as 2 minutes post-dosing.
Outlook: The company anticipates higher performance levels from new innovations with faster drug delivery. Several licensees have estimated operation launch dates ranging from Q4 2019 to Q2 2020.
Risks and Contingencies: Shares issued to Integra are subject to a six-month hold period and restrictive US legends. The contingent issuance of 180,000 shares is dependent on the non-termination of the engagement after the initial term.
Investor Verification Checklist
- Verify the actual issuance date and registration status of the 150,000 shares issued to Integra Consulting Group LLC.
- Confirm the commercial launch dates for the 11 active licenses, particularly those scheduled for Q4 2019 and Q2 2020.
- Review the specific terms of the Altria Ventures Inc. license, noting it is held by Lexaria Nicotine LLC, a separate business division.
- Monitor the fair market price of Lexaria securities prior to the potential issuance of the contingent 180,000 shares.